This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Does Masimo (MASI) Have the Potential to Rally 27.46% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Masimo (MASI) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
New Strong Buy Stocks for August 27th
by Zacks Equity Research
LYTS, PDS, STRL, MASI and DEC have been added to the Zacks Rank #1 (Strong Buy) List on August 27, 2024.
Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio
by Zacks Equity Research
Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.
Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen
by Zacks Equity Research
Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.
Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches
by Zacks Equity Research
Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.
PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS
by Zacks Equity Research
PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.
Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study
by Zacks Equity Research
Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alcon's (ALC) Market Share Gains, New Launches Aid Growth
by Zacks Equity Research
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.
Walgreens (WBA) Partners With BARDA to Boost Clinical Research
by Zacks Equity Research
Walgreens (WBA) and BARDA form a strategic partnership to bolster the decentralized clinical trial model.
Masimo (MASI) Gets New Suitors for Its Consumer Business Sale
by Zacks Equity Research
Masimo (MASI) receives unsolicited requests from multiple entities for acquiring its consumer business. The company already received a non-binding term sheet confirmation from a third party in May.
Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels
by Zacks Equity Research
Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.
Bruker (BRKR) Rolls Out the First 1.2 GHz NMR System in Asia
by Zacks Equity Research
Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.
Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US
by Zacks Equity Research
Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.
Masimo's (MASI) W1 Watch Gains FDA Nod for SafetyNet Connectivity
by Zacks Equity Research
The latest FDA clearance of Masimo's (MASI) W1 medical watch is likely to provide a continuous and accurate view of patients' health data.
Labcorp (LH) Gains From New Collaborations Amid FX Issues
by Zacks Equity Research
Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.
Quest Diagnostics (DGX) Gains From Innovation, Customer Wins
by Zacks Equity Research
A key driver in Brain Health growth is Quest Diagnostics' (DGX) Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring.
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma
by Zacks Equity Research
Thermo Fisher's (TMO) SeCore HLA Typing Kit gets FDA's 510(k) clearance for use as CDx with a TCR Therapy for synovial sarcoma
New Strong Buy Stocks for August 9th
by Zacks Equity Research
LSPD, CART, MASI, STRL and DKL have been added to the Zacks Rank #1 (Strong Buy) List on August 9, 2024.
What Makes Masimo (MASI) a New Buy Stock
by Zacks Equity Research
Masimo (MASI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Strength in Healthcare revenues drive Masimo's (MASI) second-quarter results.
Compared to Estimates, Masimo (MASI) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Masimo (MASI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 11.69% and 0.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 0% and 8.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.